BR112014008733A2 - sais de erlotinib - Google Patents
sais de erlotinibInfo
- Publication number
- BR112014008733A2 BR112014008733A2 BR112014008733A BR112014008733A BR112014008733A2 BR 112014008733 A2 BR112014008733 A2 BR 112014008733A2 BR 112014008733 A BR112014008733 A BR 112014008733A BR 112014008733 A BR112014008733 A BR 112014008733A BR 112014008733 A2 BR112014008733 A2 BR 112014008733A2
- Authority
- BR
- Brazil
- Prior art keywords
- acid salt
- erlotinib
- erlotinib salts
- mandelic
- present
- Prior art date
Links
- 150000004923 Erlotinib derivatives Chemical class 0.000 title abstract 5
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 abstract 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical class C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 abstract 2
- -1 erlotinib salts Chemical class 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 abstract 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract 1
- 229960001433 erlotinib Drugs 0.000 abstract 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
abstract the invention relates to erlotinib salts selected from the group consisting of the maleic acid salt. salicylic acid salt. l-mandelic acid alt. adipinic acid salt. 1.5-naphthalene-disulfonic acid salt. l-pyroglutamic acid salt. 1-hydroxy-2-naphthoic acid salt. and mandelic acid salt and amorphous and crystalline forms. hydrates and solvates thereof. the erlotinib salts of the present invention are useful in therapy. particularly for the treatment or prophylaxis of non-small cell lung carcinoma and pancreas rarcinoma. tradução do resumo resumo patente de invenção: "sais de erlotinib". a presente invenção refere-se aos sais de erlotinib selecio-nados do grupo consistindo em sal de ácido maleico, sal de ácido sali-cílico, sal de ácido l-mandélico, sal de ácido adipínico, sal de ácido 1,5-naftalênico-dissulfônico, sal de ácido l-piroglutâmico, sal de ácido 1-hidróxi-2-naftóico e sal de ácido mandélico e formas amorfas e cris-talinas, hidratos e solvatos dos mesmos. os sais de erlotinib da pre-sente invenção são úteis em terapia, particularmente para o tratamento ou profilaxia de carcinoma de pulmão de célula não pequena e car-cinoma do pâncreas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1100562A HU230483B1 (hu) | 2011-10-10 | 2011-10-10 | Erlotinib sók |
| PCT/HU2012/000102 WO2013054147A2 (en) | 2011-10-10 | 2012-10-10 | Erlotinib salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014008733A2 true BR112014008733A2 (pt) | 2017-04-25 |
Family
ID=89990469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014008733A BR112014008733A2 (pt) | 2011-10-10 | 2012-10-10 | sais de erlotinib |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2776406A2 (pt) |
| CN (1) | CN103958483A (pt) |
| BR (1) | BR112014008733A2 (pt) |
| EA (1) | EA201490773A1 (pt) |
| HU (1) | HU230483B1 (pt) |
| WO (1) | WO2013054147A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014118737A1 (en) * | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
| CN104250230A (zh) * | 2014-09-05 | 2014-12-31 | 亿腾药业（泰州）有限公司 | 厄洛替尼柠檬酸盐与其晶型以及它们的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| ES2238825T3 (es) | 1998-04-29 | 2005-09-01 | Osi Pharmaceuticals, Inc. | Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidrato. |
| US7960545B2 (en) * | 2005-11-23 | 2011-06-14 | Natco Pharma Limited | Process for the prepartion of erlotinib |
| KR101441930B1 (ko) | 2007-04-04 | 2014-09-19 | 시플라 리미티드 | 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법 |
| CN102438995B (zh) * | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | 厄洛替尼或其药学上可接受的盐的制备工艺 |
| WO2011068403A2 (en) * | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
-
2011
- 2011-10-10 HU HU1100562A patent/HU230483B1/hu not_active IP Right Cessation
-
2012
- 2012-10-10 EP EP12826647.5A patent/EP2776406A2/en not_active Withdrawn
- 2012-10-10 EA EA201490773A patent/EA201490773A1/ru unknown
- 2012-10-10 BR BR112014008733A patent/BR112014008733A2/pt not_active IP Right Cessation
- 2012-10-10 WO PCT/HU2012/000102 patent/WO2013054147A2/en active Application Filing
- 2012-10-10 CN CN201280058335.8A patent/CN103958483A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201490773A1 (ru) | 2014-10-30 |
| WO2013054147A2 (en) | 2013-04-18 |
| EP2776406A2 (en) | 2014-09-17 |
| WO2013054147A3 (en) | 2013-06-13 |
| HUP1100562A2 (en) | 2013-05-28 |
| CN103958483A (zh) | 2014-07-30 |
| HU230483B1 (hu) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015025260A2 (pt) | compostos heterocíclicos fundidos como inibidores da proteína quinase | |
| EA201490889A1 (ru) | Конденсированный бициклический оксазолидинон как ингибитор cetp | |
| BR112015028214A2 (pt) | inibidores de acc e usos dos mesmos | |
| BR112014013108A2 (pt) | compostos tricíclicos fundidos como inibidores da quinase raf | |
| EA201992270A2 (ru) | 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов | |
| EA201790317A1 (ru) | Ингибиторы smyd | |
| EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
| BR112016002012A2 (pt) | compostos de sulfonamida heterocíclica substituída úteis como moduladores de trpa1 | |
| DK2483255T3 (da) | Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser | |
| BR112013010018A2 (pt) | inibidores de cdk | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| BR112014030639A2 (pt) | inibidores macrocíclicos de vírus flaviviridae | |
| BR112015000561A2 (pt) | inibidores de irak e usos dos mesmos | |
| BR112014005979A2 (pt) | métodos e composições para controle de erva daninha | |
| EA201391754A1 (ru) | Иммуноконъюгаты, содержащие их композиции и способы их получения и применения | |
| BR112014010420A2 (pt) | inibidores de pak para o tratamento de distúrbios proliferativos celulares | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| MX355088B (es) | Inhibidores de tienopirimidina de proteina cinasa c atipica. | |
| BR112015021524A2 (pt) | derivados de sulfonil quinolina e usos dos mesmos | |
| EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
| EA201300867A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ | |
| EA201491303A1 (ru) | Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps | |
| BR112012023780A2 (pt) | compostos complexos de ferro (iii) - b - cetoamida ou sais farmaceuticamente toleráveis desses, processo para a produção dos compostos complexos de ferro (iii), uso de compostos complexos de ferro (iii), fármaco contendo compostos complexos de ferro (iii) e composição contendo compostos complexos de ferro (iii) | |
| BR112015017331A2 (pt) | compostos químicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |